Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Payables (2020 - 2025)

Barinthus Biotherapeutics' Payables history spans 6 years, with the latest figure at $350000.0 for Q4 2025.

  • For Q4 2025, Payables fell 85.85% year-over-year to $350000.0; the TTM value through Dec 2025 reached $350000.0, down 85.85%, while the annual FY2025 figure was $350000.0, 85.85% down from the prior year.
  • Payables reached $350000.0 in Q4 2025 per BRNS's latest filing, down from $698000.0 in the prior quarter.
  • In the past five years, Payables ranged from a high of $5.1 million in Q3 2023 to a low of $350000.0 in Q4 2025.
  • Average Payables over 5 years is $2.8 million, with a median of $2.5 million recorded in 2023.
  • Peak YoY movement for Payables: surged 113.4% in 2023, then crashed 85.85% in 2025.
  • A 5-year view of Payables shows it stood at $2.4 million in 2021, then surged by 54.94% to $3.7 million in 2022, then tumbled by 57.28% to $1.6 million in 2023, then soared by 54.53% to $2.5 million in 2024, then plummeted by 85.85% to $350000.0 in 2025.
  • Per Business Quant, the three most recent readings for BRNS's Payables are $350000.0 (Q4 2025), $698000.0 (Q3 2025), and $1.8 million (Q2 2025).